COVID-19 med APN01 selected to be tested in ACTIV study
APEIRON Biologics recombinant ACE2 APN01 has been selected to participate in the US ACTIV study. ACTIV is aimed to speed up development of the best COVID-19 meds.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1997 entries already.
Entries by Thomas Gabrielczyk
Hummingbird Bioscience raises $125m in Series C financing
Danish Novo Holdings A/S has led an oversubscribed US$125m Series C into the cancer antibody specialist Hummingbird Bioscience.
BD installs production hub in Zaraogza
BD will build a €165m manufacturing facility in Zaragoza, Spain to support the growth of its pre-filled drug delivery business.
COVID-19 therapeutics: Germany launches €300m funding
German government has launched a €300m programme designed to bring clinically tested COVID-19 treatments to the patient’s bedside.
Recombinant silk producer AMSilk raises €29m
AMSilk GmbH has closed a Series C financing at €29m to accelerate and expand commercialisation of its microbially produced silk fibres.
SARS-CoV-2-antibodies may promote severe COVID-19
Immunoglobin G antibodies (IgG) produced in response to the SARS-CoV-2 spike protein appear to play a role in how COVID-19 can turn more severe in some cases.
Abingworth raises $582m for late-stage fund ACCD 2
International life sciences investment group Abingworth has closed a new clinical co-development fund at US$582m.
USA supports to temporarily waive IP of COVID-19 vaccines
The Biden administration has announced it will support the WHO proposal to temporarily waive intellectual property rights for COVID-19 vaccines to speed up vaccination.
Swiss Oculis SA raises $57m in Series C
Topical ophthalmic therapies developer Oculis S.A. has closed a US$57m Series C financing to push development of its pipeline.
Mogrifiy completes Series A financing round
Cell reprogramming specialist Mogrify Ltd has announced the second closing of its Series A financing of $17m, bringing the total raised to $33m in this round.